KOC
Koss-Olinger Consulting’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.05M | Buy |
42,197
+9,685
| +30% | +$471K | 0.17% | 68 |
|
|
2025
Q1 | $1.11M | Sell |
32,512
-1,656
| -5% | -$56.3K | 0.09% | 109 |
|
|
2024
Q4 | $1.35M | Buy |
34,168
+18,298
| +115% | +$720K | 0.12% | 84 |
|
|
2024
Q3 | $746K | Sell |
15,870
-48
| -0.3% | -$2.26K | 0.06% | 115 |
|
|
2024
Q2 | $860K | Buy |
+15,918
| New | +$860K | 0.08% | 108 |
|
|
2024
Q1 | – | Sell |
-29,962
| Closed | -$1.88M | – | 103 |
|
|
2023
Q4 | $1.88M | Buy |
29,962
+4,802
| +19% | +$301K | 0.18% | 58 |
|
|
2023
Q3 | $1.14M | Buy |
25,160
+3,660
| +17% | +$166K | 0.17% | 78 |
|
|
2023
Q2 | $1.21M | Hold |
21,500
| – | – | 0.14% | 78 |
|
|
2023
Q1 | $972K | Buy |
+21,500
| New | +$972K | 0.12% | 94 |
|
|
2021
Q3 | – | Sell |
-12,650
| Closed | -$2.05M | – | 246 |
|
|
2021
Q2 | $2.05M | Buy |
12,650
+1,441
| +13% | +$233K | 0.3% | 35 |
|
|
2021
Q1 | $1.37M | Buy |
+11,209
| New | +$1.37M | 0.23% | 46 |
|